Company intelligence / Profile preview

I-VASC

Ownership: Private
Development stage: Commercial

Overview

VELEX™, based on EVA technology, received CE Mark in May 2021. First clinical use began in Milan with positive initial results. Post-market clinical trials are ongoing to further validate efficacy and safety. The company aims to expand into new geographies and develop additional applications for its platform.

Therapeutic areas: Cardiovascular
Modalities: DeviceNon-pharmacological therapy (minimally invasive procedure)
Industry: Surgical Medical Devices

Partnerships

Clinical partnerships with Policlinico San Donato and San Raffaele Hospital, Milan

Beyond the preview

Go deeper on I-VASC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on I-VASC.

Explore the full profile